All terms in EFO
| Label | Id | Description |
|---|---|---|
| C-C motif chemokine 27 measurement | EFO_0020198 | [The determination of the amount of C-C motif chemokine 27 in a sample] |
| Krukenberg Tumor | EFO_1000316 | [Metastatic signet-ring cell carcinoma to the ovary. The primary site is the gastrointestinal tract or breast.] |
| metastatic carcinoma | MONDO_0024879 | [A carcinoma which has spread from the original site of growth to another anatomic site.] |
| signet ring cell carcinoma | EFO_0000698 | [A usually aggressive, poorly differentiated invasive adenocarcinoma characterized by the presence of malignant glandular cells in which the nucleus is pressed to one side by the presence of intracytoplasmic mucus. It may arise from the stomach, small and large intestine, ampulla of Vater, appendix, gallbladder, pancreas, lung, bladder, breast, and prostate gland.] |
| C-C motif chemokine 28 measurement | EFO_0020199 | [The determination of the amount of C-C motif chemokine 28 in a sample] |
| brain-specific serine protease 4 measurement | EFO_0020192 | [The determination of the amount of brain-specific serine protease 4 in a sample] |
| corneal dystrophy | MONDO_0018102 | [The term corneal dystrophy embraces a heterogeneous group of bilateral genetically determined non-inflammatory corneal diseases that are usually restricted to the cornea. The designation is imprecise but remains in vogue because of its clinical value.] |
| brevican core protein measurement | EFO_0020193 | [The determination of the amount of brevican core protein in a sample] |
| Daphnia magna | NCBITaxon_35525 | |
| Wolfram syndrome | MONDO_0018105 | [Wolfram syndrome (WS) also known as DIDMOAD, is a neurodegenerative disorder characterized by type I diabetes mellitus (DM), diabetes insipidus (DI), sensorineural deafness (D), bilateral optical atrophy (OA) and neurological signs. Other related problems are urinary tract atony, ataxia, peripheral neuropathy, psychiatric disorders and/or seizures. 2 types of WS may be distinguished: type 1 and type 2 (WS1 and WS2).] |
| type 1 diabetes mellitus | MONDO_0005147 | [A chronic condition characterized by minimal or absent production of insulin by the pancreas.] |
| brother of CDO measurement | EFO_0020194 | [The determination of the amount of brother of CDO in a sample] |
| C-C motif chemokine 13 measurement | EFO_0020195 | [The determination of the amount of C-C motif chemokine 13 in a sample] |
| Daphnia pulicaria | NCBITaxon_35523 | |
| familial primary hypomagnesemia with normocalciuria and normocalcemia | MONDO_0018101 | [Familial primary hypomagnesemia with normocalciuria and normocalcemia (FPHNN) is a form of familial primary hypomagnesemia (FPH), characterized by low serum magnesium (Mg) values but inappropriate normal urinary Mg values (i.e. renal hypomagnesemia). The typical symptoms are weakness of the limbs, vertigo, headaches, seizures, brisk tendon reflexes and mild to moderate psychomotor delay.] |
| familial primary hypomagnesemia with normocalcuria | MONDO_0017626 | [Familial primary hypomagnesemia with normocalcuria (FPHN) is a form of familial primary hypomagnesemia (FPH) which is characterized by low magnesium values but normal calcium values in the serum. The disorder consists of three distinct forms which are: autosomal recessive primary hypomagnesemia with normocalcuria and hypocalcemia (ARPHN), familial primary hypomagnesemia with normocalcuria and normocalcemia (FPHNN) and isolated autosomal dominant hypomagnesemia, Glaudemans type.] |
| bone sialoprotein 2 measurement | EFO_0020190 | [The determination of the amount of bone sialoprotein 2 in a sample] |
| familial primary hypomagnesemia | MONDO_0018100 | [A hereditary disorder that leads to a selective defect in renal or intestinal magnesium absorption, resulting in a low serum magnesium concentration.] |
| disorder of magnesium transport | MONDO_0017765 | [An acquired metabolic disease that is has its basis in the disruption of magnesium ion transport.] |
| brain natriuretic peptide 32 measurement | EFO_0020191 | [The determination of the amount of brain natriuretic peptide 32 in a sample] |